{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T23:41:03Z","timestamp":1792798863491,"version":"4.5.0"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.critrevonc.2026.105248","type":"journal-article","created":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T02:01:03Z","timestamp":1772848863000},"page":"105248","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Viral hepatitis and immunotherapy outcome in advanced hepatocellular carcinoma: A comprehensive umbrella review of 15 meta-analyses"],"prefix":"10.1016","volume":"221","author":[{"given":"Fausto","family":"Petrelli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Colombo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Dottorini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mara","family":"Ghilardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annamaria","family":"De Giorgi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianluca","family":"Tomasello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulio","family":"Carcano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Ghidini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.critrevonc.2026.105248_bib1","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2100070","article-title":"Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma","volume":"1","author":"Abou-Alfa","year":"2022","journal-title":"NEJM Evid."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105248_bib2","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"issue":"10","key":"10.1016\/j.critrevonc.2026.105248_bib3","first-page":"2468","article-title":"Atezolizumab plus bevacizumab versus lenvatinib or sorafenib in non-viral unresectable hepatocellular carcinoma: an international propensity score matching analysis","volume":"13","author":"Casadei-Gardini","year":"2021","journal-title":"Cancers"},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105248_bib4","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/j.jhep.2021.11.030","article-title":"Updated efficacy and safety data from IMbrave150: atezolizumab plus bevacizumab vs sorafenib for unresectable hepatocellular carcinoma","volume":"76","author":"Cheng","year":"2022","journal-title":"J. Hepatol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105248_bib5","doi-asserted-by":"crossref","first-page":"127","DOI":"10.17998\/jlc.2022.12.30","article-title":"Non-alcoholic fatty liver disease\u2013related hepatocellular carcinoma","volume":"23","author":"Daher","year":"2023","journal-title":"J. Liver Cancer"},{"key":"10.1016\/j.critrevonc.2026.105248_bib6","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1111\/hepr.13712","article-title":"Does immune checkpoint inhibitor exhibit limited efficacy against non-viral hepatocellular carcinoma?: a review of clinical trials","volume":"52","author":"Eso","year":"2022","journal-title":"Hepatol. Res"},{"key":"10.1016\/j.critrevonc.2026.105248_bib7","unstructured":"2018. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of hepatocellular carcinomaJ. Hepatol.69118223610.1016\/j.jhep.2018.03.019."},{"issue":"20","key":"10.1016\/j.critrevonc.2026.105248_bib8","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N. Engl. J. Med"},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105248_bib9","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1053\/j.gastro.2021.06.008","article-title":"Evidence-based management of hepatocellular carcinoma: systematic review and meta-analysis of randomized controlled trials (2002-2020)","volume":"161","author":"Haber","year":"2021","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105248_bib10","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1002\/hep.29086","article-title":"AASLD guidelines for the treatment of hepatocellular carcinoma","volume":"67","author":"Heimbach","year":"2018","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105248_bib11","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1053\/j.gastro.2020.09.031","article-title":"Steatohepatitis impairs T-cell-directed immunotherapies against liver tumors in mice","volume":"160","author":"Heinrich","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1016\/j.critrevonc.2026.105248_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.clinre.2022.102061","article-title":"Comparison of the effects of lenvatinib and sorafenib on survival in patients with advanced hepatocellular carcinoma: a systematic review and meta-analysis","author":"Hu","year":"2023","journal-title":"Clin. Res Hepatol. Gastroenterol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105248_bib13","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1186\/s12885-023-10960-w","article-title":"Efficacy and safety of PD-1\/PD-L1 inhibitors combined with anti-angiogenic therapy for unresectable hepatocellular carcinoma and benefit for hepatitis B virus aetiology subgroup: a systematic review and meta-analysis of randomized controlled trials","volume":"23","author":"Huang","year":"2023","journal-title":"BMC Cancer"},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105248_bib14","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1503\/cmaj.081086","article-title":"Integration of evidence from multiple meta-analyses: a primer on umbrella reviews, treatment networks and multiple treatments meta-analyses","volume":"181","author":"Ioannidis","year":"2009","journal-title":"CMAJ"},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105248_bib15","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1503\/cmaj.081086","article-title":"Integration of evidence from multiple meta-analyses: A primer on umbrella reviews, treatment networks and multiple treatments meta-analyses","volume":"181","author":"Ioannidis","year":"2009","journal-title":"CMAJ"},{"key":"10.1016\/j.critrevonc.2026.105248_bib16","article-title":"Umbrella Reviews: Concepts, Methodological Frameworks, and Step-by-Step Implementation","volume":"0","author":"Liu","year":"2025","journal-title":"J. Evid. Based Med."},{"key":"10.1016\/j.critrevonc.2026.105248_bib17","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.36128","article-title":"Efficacy and safety associated with immune checkpoint inhibitors in unresectable hepatocellular carcinoma: a meta-analysis","author":"J\u00e1come","year":"2021","journal-title":"JAMA Netw. Open"},{"issue":"10126","key":"10.1016\/j.critrevonc.2026.105248_bib18","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","article-title":"Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial","volume":"391","author":"Kudo","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.critrevonc.2026.105248_bib19","doi-asserted-by":"crossref","DOI":"10.1177\/15330338241305700","article-title":"PD-1\/PD-L1 inhibitors plus antiangiogenic drugs versus sorafenib as the first line treatment for advanced hepatocellular carcinoma: a phase 3 RCTs based meta-analysis","author":"Li","year":"2024","journal-title":"Technol. Cancer Res Treat."},{"key":"10.1016\/j.critrevonc.2026.105248_bib20","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1667793","article-title":"First-line immune checkpoint inhibitors plus targeted therapy versus sorafenib or lenvatinib monotherapy for unresectable or advanced hepatocellular carcinoma: a meta-analysis of phase 3 trials","author":"Lin","year":"2025","journal-title":"Front Immunol."},{"key":"10.1016\/j.critrevonc.2026.105248_bib21","article-title":"Efficacy and safety of atezolizumab plus bevacizumab versus lenvatinib for unresectable hepatocellular carcinoma: a systematic review and meta-analysis","author":"Liu","year":"2023","journal-title":"J. Cancer Res Clin. Oncol."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105248_bib22","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1056\/NEJMoa0708857","article-title":"Sorafenib in advanced hepatocellular carcinoma","volume":"359","author":"Llovet","year":"2008","journal-title":"N. Engl. J. Med"},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105248_bib23","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s12072-017-9799-9","article-title":"Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update","volume":"11","author":"Omata","year":"2017","journal-title":"Hepatol. Int"},{"issue":"7854","key":"10.1016\/j.critrevonc.2026.105248_bib24","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/s41586-021-03362-0","article-title":"NASH limits anti-tumour surveillance in immunotherapy-treated HCC","volume":"592","author":"Pfister","year":"2021","journal-title":"Nature"},{"issue":"7854","key":"10.1016\/j.critrevonc.2026.105248_bib25","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/s41586-021-03362-0","article-title":"NASH limits anti-tumour surveillance in immunotherapy-treated HCC","volume":"592","author":"Pfister","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.critrevonc.2026.105248_bib26","doi-asserted-by":"crossref","DOI":"10.3390\/curroncol30010057","article-title":"Immune-based combinations versus sorafenib as first-line treatment for advanced hepatocellular carcinoma: a meta-analysis","author":"Rizzo","year":"2023","journal-title":"Curr. Oncol."},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105248_bib27","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1016\/j.jhep.2020.07.026","article-title":"Association of inflammatory biomarkers with clinical outcomes in nivolumab-treated patients with advanced hepatocellular carcinoma","volume":"73","author":"Sangro","year":"2020","journal-title":"J. Hepatol."},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105248_bib28","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1038\/s41575-021-00438-0","article-title":"Advances in immunotherapy for hepatocellular carcinoma","volume":"18","author":"Sangro","year":"2021","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.critrevonc.2026.105248_bib29","doi-asserted-by":"crossref","first-page":"j4008","DOI":"10.1136\/bmj.j4008","article-title":"AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both","volume":"358","author":"Shea","year":"2017","journal-title":"BMJ"},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105248_bib30","first-page":"209","article-title":"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.critrevonc.2026.105248_bib31","doi-asserted-by":"crossref","DOI":"10.1007\/s11523-024-01035-2","article-title":"Lenvatinib versus atezolizumab plus bevacizumab in the first-line treatment for unresectable hepatocellular carcinoma: a meta-analysis of real-world studies","author":"Wang","year":"2024","journal-title":"Target Oncol."},{"key":"10.1016\/j.critrevonc.2026.105248_bib32","doi-asserted-by":"crossref","DOI":"10.1007\/s00228-024-03797-0","article-title":"Quantitative evaluation of the efficacy and safety of first-line systemic therapies for advanced hepatocellular carcinoma","author":"Wang","year":"2025","journal-title":"Eur. J. Clin. Pharm."},{"issue":"11","key":"10.1016\/j.critrevonc.2026.105248_bib33","doi-asserted-by":"crossref","first-page":"3590","DOI":"10.1097\/JS9.0000000000000652","article-title":"Clinico-characteristics of patients which correlated with preferable treatment outcomes in immunotherapy for advanced hepatocellular carcinoma: a systematic review and meta-analysis","volume":"109","author":"Wang","year":"2023","journal-title":"Int J. Surg."},{"issue":"11","key":"10.1016\/j.critrevonc.2026.105248_bib34","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2020.4564","article-title":"Efficacy and safety of nivolumab plus ipilimumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib: the CheckMate 040 randomized clinical trial","volume":"6","author":"Yau","year":"2020","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.critrevonc.2026.105248_bib35","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2022.109244","article-title":"Benefits of combination therapy with immune checkpoint inhibitors and predictive role of tumour mutation burden in hepatocellular carcinoma: a systematic review and meta-analysis","author":"Zheng","year":"2022","journal-title":"Int Immunopharmacol."},{"key":"10.1016\/j.critrevonc.2026.105248_bib36","doi-asserted-by":"crossref","DOI":"10.1007\/s00228-024-03718-1","article-title":"Is atezolizumab plus bevacizumab as first-line therapy for unresectable hepatocellular carcinoma superior to lenvatinib? a systematic review and meta-analysis","author":"Zhu","year":"2024","journal-title":"Eur. J. Clin. Pharm."}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842826001356?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842826001356?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T11:52:40Z","timestamp":1775908360000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842826001356"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":36,"alternative-id":["S1040842826001356"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105248","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Viral hepatitis and immunotherapy outcome in advanced hepatocellular carcinoma: A comprehensive umbrella review of 15 meta-analyses","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105248","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"105248"}}